Cardiovascular and non‐cardiovascular safety of dipeptidyl peptidase‐4 inhibition: a meta‐analysis of randomized controlled cardiovascular outcome trials
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The full licensing of dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors in the USA and E urope requires demonstration of cardiovascular ( CV ) safety with an upper boundary of harm of <30%. We report a total of 3334 CV events during 86 716 person‐years of follow‐up in 36 543 patients, when combining data from three trials with formal and prospectively assessed endpoints. Fixed‐effect meta‐analysis showed that, compared with placebo, DPP ‐4 inhibition did not increase the upper boundary of risk for the composite endpoint, nor for any individual component by >30%. Relative risks ( RRs ) were: 0.99 [confidence interval ( CI ) 0.93–1.06] for composite CV ‐specific death, non‐fatal myocardial infarction ( MI ) and non‐fatal stroke; 1.01 ( CI 0.91–1.12) for CV ‐specific death; 0.98 ( CI 0.89–1.09) for non‐fatal MI ; and 1.00 ( CI 0.86–1.16) for non‐fatal stroke. The risk of acute pancreatitis was increased ( RR 1.79; CI 1.13–2.81), equating to 5.5 extra cases/10 000 patients/year (weighted mean) and a number needed to harm of 1940/year. These data provide reassurance about the safety of DPP ‐4 inhibitors with regard to individual atherothrombotic events and a safety signal for pancreatitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 6×
“296 Abbas et al. Volume 18 No. 3 March 2016 DIABETES, OBESITY AND METABOLISM research letter Study a/ Cardiovascular death + non fatal myocardial infaction + non fatal stroke b/ Cardiovascular death c/ Non fatal myocardial infarction d/ Non fatal stroke e/ Hospitalization for heart failure f/ Acute pancreatitis g/ Pan…”
MethodSelf-citationEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · cited 4×
“296 Abbas et al. Volume 18 No. 3 March 2016 DIABETES, OBESITY AND METABOLISM research letter Study a/ Cardiovascular death + non fatal myocardial infaction + non fatal stroke b/ Cardiovascular death c/ Non fatal myocardial infarction d/ Non fatal stroke e/ Hospitalization for heart failure f/ Acute pancreatitis g/ Pan…”
MethodInfluentialAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 5×
“296 Abbas et al. Volume 18 No. 3 March 2016 DIABETES, OBESITY AND METABOLISM research letter Study a/ Cardiovascular death + non fatal myocardial infaction + non fatal stroke b/ Cardiovascular death c/ Non fatal myocardial infarction d/ Non fatal stroke e/ Hospitalization for heart failure f/ Acute pancreatitis g/ Pan…”
MethodInfluentialPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Karagiannis, T., Paschos, P., Paletas, K., Matthews, D. R., & Tsapas, A. (2012) · BMJ · doi:10.1136/bmj.e1369 · Cited by 435 · cited 1×
“This innovative class of oral hypoglycaemic agents offers several advantages over existing therapies, including a once-daily preparation, weight neutrality and glucose-dependent release of insulin [6,7].”
Background
Cited by
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Clinical Use of DPP-4 Inhibitors
Gallwitz, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00389 · Cited by 374
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
Scheen, A. J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311588 · Cited by 286
Storgaard, H., Cold, F., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12885 · Cited by 155
“ing committees in 2 of them, found an increased risk of AP in DPP4i-treated patients.(10,11) The mechanism(s) underlying the apparently different risk of AP with GLP-1RAs vs DPP4is remains unclear,”
Steinberg, W. M., Buse, J. B., Ghorbani, M. L. M., Ørsted, D. D., Nauck, M. A., the LEADER Steering Committee, & on behalf of the LEADER Trial Investigators (2017) · Diabetes Care · doi:10.2337/dc16-2747 · Cited by 87
Metadata
- Authors
- Abbas, A. S., Dehbi, H. ‐., & Ray, K. K.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2015-12-23
- Volume
- 18
- Issue
- 3
- Pages
- 295-299
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1930603471
- Cited by
- 62
- References
- 5
- FWCI
- 8.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular and non‐cardiovascular safety of dipeptidyl peptidase‐4 inhibition: a meta‐analysis of randomized controlled cardiovascular outcome trials. https://app.cochat.ai/papers/10.1111/dom.12595
- The paper
- Abbas, A. S., Dehbi, H. ‐., & Ray, K. K. (2016). Cardiovascular and non‐cardiovascular safety of dipeptidyl peptidase‐4 inhibition: a meta‐analysis of randomized controlled cardiovascular outcome trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12595
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.